Isabella Ciccone, Assistant Editor, NeurologyLive®, has been with the team since September 2022. Follow her on Twitter @iciccone7 or email her at iciccone@mjhlifesciences.com
Impact of Antiepileptic Medications and Sex Hormones on Maternal and Child Outcomes in Epilepsy
April 18th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
Analysis on the Efficacy of Cenobamate in Pediatric Patients With Refractory Epilepsy
April 17th 2024Kate Labiner, MD, a pediatric epileptologist at Child Neurology Consultants of Austin, talked about the potential of cenobamate in pediatric patients with refractory focal epilepsy who have failed multiple medications.
Pridopidine Maintains Effectiveness in Huntington Disease Without Antidopaminergic Medications
April 14th 2024New findings from the phase 3 PROOF-HD trial showed that pridopidine outperformed placebo up to 78 weeks in patients with Huntington disease even after excluding those on neuroleptics and antichorea medications.
Surveying the Effect of Cannabis Use for Migraine and Headache Management
April 2nd 2024Allison Verhaak, PhD, a clinical psychologist from Ayer Neuroscience Institute at Hartford Healthcare Headache Center, shared her insights on a recent study that explored cannabis use among patients with headache and migraine.
NeurologyLive® Clinician of the Month Spotlight: Scott Newsome, DO, MSCS, FAAN, FANA
March 31st 2024As part of our monthly clinician spotlight, NeurologyLive® highlighted multiple sclerosis expert Scott Newsome, DO, MSCS, FAAN, FANA, director of the Stiff Person Syndrome Center and professor of neurology at Johns Hopkins Medicine.
FDA Approves Alexion's Ravulizumab-cwvz for Neuromyelitis Optica Spectrum Disorder
March 25th 2024The approval is supported by phase 3 data which showed ravulizumab-cwvz met its primary end point of time to first on-trial relapse, with no relapses observed in 58 patients with NMOSD over a median treatment duration of 73 weeks.